UCB RYSTIGGO and BIMZELX: Never a dull moment
After a stressful few weeks, UCB announced yesterday that the FDA will require further time to process the much awaited US approval for the use of Bimzelx in the treatment of moderate to severe psoriasis. While this clearly will create additional stress with UCB investors, we believe that the chances for ultimate approval are still high (and unchanged). Today, UCB announces that Rystiggo (rozanolixizumab) did get FDA approval for the treatment of gMG, allowing it to go head to head with Vyvgart (both FcRn inhibitors). While the Bimzelx news decreased our PT somewhat, the RYSTIGGO news offsets this. Thus, overall, we stay bullish, reiterate our Buy rating and € 110 PT.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.